Development of an innovative compression sleeve for breast cancer-related arm lymphoedema

Reference number 2018-03866
Coordinator PRESSCISE AB
Funding from Vinnova SEK 940 000
Project duration January 2019 - December 2019
Status Ongoing
Venture Medtech4Health - medicintekniska samverkansprojekt
Call Medtech4Health: Collaboration projects involving medical technology 2018

Purpose and goal

Lymphedema is a progressive, chronic condition that affects a large number of people and their physical and psychosocial health. The primary cause is a side effect of cancer treatment, where the incidence of breast cancer patients is 12-60%. During the project, an innovative compression sleeve for arms will be developed in collaboration between PressCise AB and Physical Therapy Sahlgrenska. The arm sleeve will be validated and verified on patients with breast cancer-related arm lymphedema.

Expected results and effects

The poor fit and poor patient compliance with today´s standard sleeves, as well as high costs for custom made sleeves, leads either to very bad or very expensive medical treatment. A more efficient treatment would result in several benefits. For the patient it would mean reduced lymphedema, less pain, shorter sick leave, better comfort and mobility and overall better quality of life. A better compression sleeve would also mean cheaper (shorter) treatments, fewer hospital visits and lower insurance costs for sick leave.

Planned approach and implementation

The project is divided into three work packages (AP). During AP 1, the focus will be on developing a requirement specification and product development to produce a number of prototypes. During AP 2, the prototypes will be evaluated in a clinical setting, on patients with breast cancer-related arm lymphedema. During AP 3, focus will be on business development and marketing strategies for commercializing the final product.

External links

The project description has been provided by the project members themselves and the text has not been examined by our editors.